Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Teva Pharmaceuticals International has offered to acquire neuroscience assets from BioXcel Therapeutics for a total deal value of up to $125 million. This agreement is part of BioXcel Therapeutics' voluntary Chapter 11 bankruptcy proceedings, initiating a court-supervised sale of its main assets. Teva would obtain worldwide rights to Igalmi (dexmedetomidine) sublingual film and the investigational BXCL501, which is currently under FDA review for potential at-home use in treating acute agitation.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
CoreWeave's default probability exceeds 60%, but NVIDIA CEO Jensen Huang states its financing costs are decreasing and NVIDIA is not required to backstop it.
-
2
UKMTO Warns of "Severe" Threat to Shipping in Strait of Hormuz, Attacks "Highly Likely"
-
3
CoreWeave Credit Default Swaps Hit Distressed Levels Amid Investor Concerns Over AI Debt
-
4
MSCI adopts new index exclusion rules; Strategy and Metaplanet may face removal, SharpLink placed on review list.
-
5
Fed's Hammack: Financial conditions do not appear restrictive right now
-
6
US embassy warns of potential attacks on Saudi airports, restricts staff travel and urges citizens to take extreme caution
-
7
MSCI Launches Consultation to Reclassify Indonesia Equity Indexes from Emerging to Standalone Market Status
-
8
Porsche CEO Michael Leiters discusses new Mission S supercar, China market, and future of EVs
-
9
Jensen Huang Responds to AI Compute Investment Anxiety: Backs CoreWeave, Says Market Misreads Compute Demand
-
10
Balaji Srinivasan's Network School acquires Farcaster; users must sign 'social smart contract' or get read-only access
Markets Today
Recommended Reading


